In squamous cell carcinoma, tumour-initiating cells acquired the immune checkpoint molecules CD80 and CD276 to evade immunological surveillance from cytotoxic lymphocytes during local recurrence and metastasis16,17. This evidence concerns the gene CD80 and squamous cell carcinoma.